Biotech billionaire Kirk has a new, much bigger top line in mind

Randal "RJ" Kirk has made billions in the biotech business by focusing on the development of new and improved drugs. But now the CEO of synthetic biotech pioneer Intrexon ($XON) is thinking outside the healthcare box. "Biotech has a reverse footprint on the world. You should think beyond healthcare because if you want to know where the rapid growth in biotech is going to occur, it's going to be, in my opinion, highest in consumer, second highest in industrial, third highest in agriculture and then therapeutics," he told an audience in Florida. Story

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.